Crossmark

Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?

Crossref DOI link: https://doi.org/10.1016/j.artere.2019.04.002

Published Print: 2020-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Piqueras Ruiz, Sandra

Parra Virto, Alejandro

Torres do Rego, Ana

Demelo Rodríguez, Pablo

Álvarez-Sala Walther, Luis
Funding

Funding for this research was provided by:

Sanofi

Amgen

Pfizer

MSD

AstraZeneca
License Information

Text and Data Mining valid from 2020-01-01
More Information

This article is maintained by: Elsevier

Article Title: Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?

Journal Title: Clínica e Investigación en Arteriosclerosis (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.artere.2019.04.002

Content Type: article

Copyright: © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.

Document is current

Any future updates will be listed below